Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Gilead Sciences, Inc. — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.59 (market cap $384.59M), while Gilead Sciences, Inc. trades at $147 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 473.5× YieldMax COIN Option Income Strategy ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while YieldMax COIN Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax COIN Option Income Strategy ETF for 41 Days and Gilead Sciences, Inc. for 111 Days on average.
| CONY | GILD | |
|---|---|---|
Market Cap | $384.59M | $182.09B |
Volume | 792,653 | 4,960,247 |
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $155.80 |
52-Week Low | $17.73 | $116.74 |
Typical Hold Time | 41 Days | 111 Days |
Enterprise Value | — | $205.15B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.16, down 3.38% today, with a bearish technical outlook as moving averages signal selling pressure. The ETF maintains weekly dividend distributions but faces structural NAV erosion concerns. Recent news highlights regulatory uncertainty impacting crypto-related stocks after Senate cryptocurrency legislation failed to advance.
The outlook remains challenging with significant YTD price decline and ongoing NAV decay despite high distribution rates. Investment opportunity exists for income-focused investors seeking weekly dividends, but structural risks and crypto market volatility present substantial downside exposure.
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
